Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy and safety results from a phase 2, open-label study

被引：0

作者：

Lim, Young-Suk ^{[1
]}

Lin, Chun-yen ^{[2
,3
]}

Heo, Jeong ^{[4
]}

Bae, Ho ^{[5
]}

Chuang, Wan-Long ^{[6
]}

Tsang, Tak Yin Owen ^{[7
]}

Fournier, Claire ^{[8
]}

Hui, Aric Josun ^{[9
]}

Huy Trinh ^{[10
]}

Tan, Susanna ^{[11
]}

Zhao, Yang ^{[11
]}

Flaherty, John F. ^{[11
]}

Suri, Vithika ^{[11
]}

Gaggar, Anuj ^{[11
]}

Brainard, Diana ^{[11
]}

Ryder, Stephen ^{[12
,13
]}

Janssen, Harry L. A. ^{[14
]}

机构：

[1] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[2] Chang Gung Univ, Taoyuan, Taiwan

[3] Chang Gung Mem Hosp, Taoyuan, Taiwan

[4] Pusan Natl Univ, Sch Med, Pusan, South Korea

[5] Asian Pacific Liver Ctr, Los Angeles, CA USA

[6] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan

[7] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[8] CHUM, Serv Hepatol, Montreal, PQ, Canada

[9] Alice Ho Miu Ling Nethersole Hosp, Tai Po, Hong Kong, Peoples R China

[10] San Jose Gastroenterol, San Jose, CA USA

[11] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[12] Nottingham Univ Hosp NHS Trust, Biomed Res Ctr Gastrointestinal & Liver Disorders, Nottingham, England

[13] Univ Nottingham, Nottingham, England

[14] Erasmus MC, Rotterdam, Netherlands

来源：

JOURNAL OF HEPATOLOGY | 2021年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

PO-2338

引用

页码：S755 / S756

页数：2

共 50 条

[31] Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B
Chan, H. L.
Fung, S.
Seto, W. K.
Gane, E.
Flaherty, J. F.
Suri, V.
Lin, L.
Gaggar, A.
Subramanian, G. M.
Chuang, W. L.
Agarwal, K.
Janssen, H. L.
Buti, M.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S25 - S25
[32] COST-EFFECTIVENESS OF SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALAFENAMIDE VS. ENTECAVIR FOR CHRONIC HEPATITIS B PATIENTS IN GREECE
Sinakos, E.
Kachru, N.
Tsoulas, C.
Jeyakumar, S.
Smith, N.
Yehoshua, A.
Cholongitas, E.
VALUE IN HEALTH, 2023, 26 (06) : S82 - S83
[33] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE AFTER SWITCHING FROM ENTECAVIR IN PATIENTS WITH CHRONIC HEPATITIS B
Hann, Hie-Won L.
Park, Grace
Bin Park, Kyong
Juon, Hee-Soon
HEPATOLOGY, 2021, 74 : 480A - 480A
[34] 1 YEAR SAFETY AND EFFICACY DATA IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TENOFOVIR DISOPROXIL FUMARATE (TDF) AFTER SWITCHING FROM TDF TO TENOFOVIR ALAFENAMIDE (TAF)
Pan, Calvin Q.
Gane, Edward
Seto, Wai-Kay
Janssen, Harry L.
Caruntu, Florin
Kim, Hyung Joon
Abdurakhmanov, Dzhamal
Nishiguchi, Shuhei
Bae, Ho
Mo, Shuyuan
Suri, Vithika
Gaggar, Anuj
Flaherty, John F.
Kao, Jia-Horng
Brunetto, Maurizia Rossana
Buti, Maria
GASTROENTEROLOGY, 2018, 154 (06) : S1132 - S1133
[35] IMPACT OF COADMINISTRATION WITHOUT OR WITH FOOD ON THE 96-WEEK EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TAF
Kao, Jia-Horng
Chuang, Wan-Long
Chen, Chi-Yi
Ahn, Sang Hoon
Fung, Scott K.
Elkhashab, Magdy
Hann, Hie-Won L.
Ravendhran, Natarajan
Nguyen, Tuan T.
Tan, Susanna
Flaherty, John F.
Gagger, Anuj
Gao, Bing
Brainard, Diana M.
Phan, Charles G.
Lim, Young-Suk
Ferret, Maria Asuncion Buti
Lampertico, Pietro
HEPATOLOGY, 2020, 72 : 484A - 484A
[36] IMPACT OF PRIOR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT DURATION ON TENOFOVIR ALAFENAMIDE (TAF) SAFETY PROFILE IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TDF TO TAF
Chan, Henry Lik Yuen
Lampertico, Pietro
Ahn, Sang Hoon
Fung, Scott K.
Bae, Ho S.
Ramji, Alnoor
Lee, June Sung
Shafran, Stephen David
Gordon, Stuart C.
Phan, Charles G.
Tan, Susanna
Flaherty, John F.
Gaggar, Anuj
Wu, George
Suri, Vithika
Lau, Daryl
Byun, Kwan Soo
Agarwal, Kosh
Lim, Young-Suk
Buti, Maria
HEPATOLOGY, 2019, 70 : 287A - 288A
[37] BONE AND RENAL SAFETY ARE IMPROVED IN CHRONIC HBV PATIENTS 1 YEAR AFTER SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF)
Chan, Henry Lik Yuen
Seto, Wai Kay
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Kao, Jia-Horng
Streinu-Cercel, Adrian
Nurmukhametova, Elena
Ma, Xiaoli
Tabak, Fehmi
Jablkowski, Maciej
Suri, Vithika
Flaherty, John
Lau, Audrey
Gaggar, Anuj
Mo, Shuyuan
Chowdhury, Abhijit
Fung, Scott
Chuang, Wan-Long
Gane, Edward
GUT, 2019, 68 : A141 - A142
[38] IMPACT OF PRIOR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT DURATION ON TENOFOVIR ALAFENAMIDE (TAF) SAFETY PROFILE IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TDF TO TAF
Chan, Henry Lik Yuen
Lampertico, Pietro
Ahn, Sang Hoon
Fung, Scott
Bae, Ho
Ramji, Alnoor
Lee, Jung Sung
Shafran, Stephen
Gordon, Stuart
Phan, Charles
Tan, Susanna
Flaherty, John
Gaggar, Anuj
Wu, George
Suri, Vithika
Lau, Daryl
Byun, Kwan Soo
Agarwal, Kosh
Lim, Young-Suk
Buti, Maria
GUT, 2020, 69 : A74 - A75
[39] Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year after Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF)
Seto, Wai Kay Walter
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Kao, Jia-Horng
Streinu-Cercel, Adrian
Nurmukhametova, Elena
Ma, Xiaoli
Tabak, Fehmi
Jablkowski, Maciej
Suri, Vithika
Flaherty, John F.
Lau, Audrey H.
Gaggar, Anuj
Mo, Shuyuan
Chowdhury, Abhijit
Fung, Scott K.
Chuang, Wan-Long
Gane, Edward J.
HEPATOLOGY, 2018, 68 : 240A - 241A
[40] Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B
Tseng, Tzu-Ning
Chen, Chien-Hung
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (05) : 916 - 917

← 1 2 3 4 5 →